ReviewFrontiers in endocrinology2025
Crosstalk of kidney and brain in diabetes-related cognitive impairment and therapeutic strategies.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Renoprotection by 5-Methoxytryptophan in Kidney Disease.Biomolecules · 2026Review
- Diabetes and postoperative cognitive dysfunction and delirium in adults: mechanisms, biomarkers, and clinical management.Frontiers in endocrinology · 2026Review
- Ketogenic metabolic therapy: low-carbohydrate interventions as novel neuroprotective strategies for cognitive dysfunction in diabetes.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) and its associated complications pose a global health threat. Notably, the rise in diabetes-induced cognitive dysfunction has garnered widespread attention. T2DM patients frequently face an elevated risk of both cognitive impairment and diabetic kidney disease (DKD) comorbidity. There is evidence to suggest that kidney and brain dysfunction share common pathogenic factors, such as vascular endothelial injury, oxidative stress, and inflammation activation. Whereas, the underlying mechanisms of kidney-brain interaction and effective treatments for DKD-related cognitive decline remain incompletely understood. Our review preliminarily summarized the relationship between renal dysfunction and cognitive decline based on the existing clinical trial evidence. The mechanisms underlying DKD-related cognitive decline which mainly included the accumulation of harmful metabolites, inflammation activation and endothelial dysfunction were also clarified. And the brain renin-angiotensin-aldosterone system (RAAS) may serve as a bridge connecting renal dysfunction in DKD with cognitive impairment. In addition, we further concluded that potential lifestyle interventions and pharmacological approaches, including antioxidants, RAS inhibitors, finerenone and hypoglycemic agents, such as sodium-glucose cotransporter-2 inhibitors, liraglutide and pioglitazone may exert the preservation of cognitive function. The review could offer valuable insights for therapeutic strategies of cognitive impairment associated with diabetes and DKD in future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.